Stock events for GlucoTrack, Inc. (GCTK)
GlucoTrack, Inc.'s stock price has experienced significant volatility and a substantial decrease in the past six months. Key events impacting the stock include continued poor financial performance and going-concern doubts, a dilutive private placement, patent approvals, financing activities, and clinical progress and presentations.
Demand Seasonality affecting GlucoTrack, Inc.’s stock price
There is no specific information available regarding the demand seasonality for GlucoTrack, Inc.'s products and services. The company is primarily in the clinical development stage and pre-revenue, with its main product, the implantable CBGM, still investigational, product demand seasonality is not a publicly discussed or significant factor at this time.
Overview of GlucoTrack, Inc.’s business
GlucoTrack, Inc. is a medical device and technology company focused on developing innovative diabetes management solutions. The company is developing a long-term implantable Continuous Blood Glucose Monitor (CBGM) system designed to measure real-time blood glucose levels directly from the blood. GlucoTrack also previously developed a non-invasive glucose monitoring device and is exploring expanded applications like epidural glucose monitoring.
GCTK’s Geographic footprint
GlucoTrack, Inc. is headquartered in Rutherford, New Jersey, United States. The company's primary focus for its implantable CBGM system is the U.S., targeting insulin-dependent individuals or those at risk of hypoglycemia. GlucoTrack has also initiated long-term, multicenter feasibility studies for its CBGM system in Australia, with original research and development efforts beginning in Israel.
GCTK Corporate Image Assessment
GlucoTrack's brand reputation appears to be a mix of promising product reception and challenging financial perceptions. A market research study indicated that over half of diabetes patients surveyed were receptive to the company's Continuous Blood Glucose Monitor (CBGM) concept. However, GlucoTrack has received a consensus "Sell" rating from analysts, and the company's stock performance reflects investor concerns about its financial position.
Ownership
GlucoTrack, Inc.'s ownership structure is heavily skewed towards retail investors and insiders, with relatively low institutional ownership. As of March 3, 2026, GlucoTrack has 11 institutional owners holding a total of 63,972 shares. John Ballantyne is reported as the largest individual shareholder, owning approximately 3.77 million shares. Insider sentiment has been strongly positive.
